Gel4Med
Gel4Med is a commercial-stage biomaterials company that develops FDA 510(k)-cleared self-assembling peptide matrices (G4Derm Plus and Suprello) for complex wound care and surgical reconstruction, serving hospitals, wound care clinics, and VA/DoD medical facilities in the United States.
- Company typePrivate
- Founded2023
- HeadquartersAllston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gel4Med does
Gel4Med is a commercial-stage biomaterials company that develops peptide-based therapeutic matrices for wound care, surgical reconstruction, and regenerative medicine. The company was founded out of Harvard Innovation Labs and is headquartered in Brighton, Massachusetts, with an R&D laboratory co-located at the University of Massachusetts Lowell's M2D2 facility. It currently commercializes two FDA 510(k)-cleared products — G4Derm Plus, a flowable biomimetic matrix for managing complex wounds including diabetic, pressure, venous, and arterial ulcers as well as surgical and burn wounds; and Suprello, a peptide-based surgical wound matrix targeting high-risk surgical cases with antibacterial protection against multidrug-resistant organisms. Both products are built on Gel4Med's proprietary, patented Smart Materials Platform (SMP), which uses self-assembling peptide technology to form 3D scaffolds that mimic the human extracellular matrix. The SMP architecture enables tunable properties including adaptable form factors (flowable, spray, film), customizable biodegradation rates, biomechanical tunability, stimuli responsiveness, and antimicrobial capability without donor-source biological variability or resistance-development risk typical of conventional antibiotics.
Gel4Med sells its products in the United States through a hybrid go-to-market model: direct enterprise field sales to hospital systems and wound care clinics, dedicated government sales to VA and DoD medical facilities (via a federal contractor with DUNS, CAGE, and NAICS registrations), and distribution partnerships — most notably with Spartan Medical for the VA/DoD channel and with Summit Products Group alongside MiMEDX Group for acute-care and surgical-suite hospital-system access. The company holds a unique CMS HCPCS Level II reimbursement code (A2037) for G4Derm Plus, enabling standardized insurance billing. Pricing is not publicly disclosed and is structured as unit-based per-SKU sales (e.g., 2ml prefilled syringes), with separate ordering channels for government and non-government buyers. Beyond commercial products, the company maintains an active R&D pipeline — including a spinal cord injury cell therapy candidate developed with the University of Miami's Miami Project to Cure Paralysis under a $1.75M CDMRP/DoD grant — that leverages the SMP into higher-value regenerative medicine applications.
The company is funded primarily through non-dilutive grants from federal and state sources, including NIH (SBIR Phase II and Commercial Readiness Pilot), the Department of Defense (CDMRP), MassVentures, the Massachusetts Life Sciences Center, and the National Science Foundation, with strategic support from Harvard Innovation Labs and Breakout Labs. Gel4Med holds registered trademarks for G4Derm Plus and Suprello and patents covering its Smart Materials Platform. Headcount is reported in the 11-50 range, led by Co-Founder and CEO Manav Mehta, PhD, with an advisory board that includes the former Chief Scientific Officer of Integra Life Sciences.
Gel4Med firmographics
Firmographics- Name
- Gel4Med
- Legal name
- Gel4Med, Inc.
- Website
- https://gelformed.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gel4Med is a commercial-stage biomaterials company that develops FDA 510(k)-cleared self-assembling peptide matrices (G4Derm Plus and Suprello) for complex wound care and surgical reconstruction, serving hospitals, wound care clinics, and VA/DoD medical facilities in the United States.
- Ownership category
- akta.pro rank
Gel4Med industry classification
Industry- Product category
- Wound Care Biomaterials
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Gel4Med is headquartered
LocationHeadquarters
- HQ city
- Allston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Gel4Med business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Product Sales - G4Derm Plus and Suprello: Commercial-stage company generating revenue through sales of FDA 510(k)-cleared wound care products G4Derm Plus and Suprello. Products sold as medical devices through government and non-government channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | G4Derm Plus Biomimetic Matrix (SKU: G4M200M, 2ml unit) |
| Unit Pricing | Pay-as-you-go | Suprello Surgical Wound Matrix (SKU: G4M100M, 2ml unit) |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Gel4Med product offering
Product offeringCore offering
Gel4Med develops and commercializes FDA 510(k)-cleared, peptide-based biomimetic matrices for advanced wound care and surgical reconstruction. Its two commercial products, G4Derm Plus (a flowable biomimetic matrix for complex chronic wounds) and Suprello (a surgical wound matrix for high-risk surgical cases), are built on its proprietary Smart Materials Platform using self-assembling peptides that mimic the human extracellular matrix to support tissue regrowth while providing antibacterial protection.
Product overview
Gel4Med is a commercial-stage biomaterials company founded out of Harvard Innovation Labs, utilizing its proprietary Smart Materials Platform (SMP™) — a patented bioengineering technology based on self-assembling peptides — to develop and commercialize therapeutic biomaterials for wound care, surgical reconstruction, and regenerative medicine. The company's product portfolio consists of two FDA 510(k)-cleared products: G4Derm™ Plus (a flowable biomimetic matrix for managing complex wounds, including diabetic ulcers, pressure ulcers, venous/arterial/mixed-etiology lower extremity ulcers, surgical wounds, and partial-thickness burns) and Suprello™ (a peptide-based surgical wound matrix targeting high-risk surgical cases with antibacterial protection). Both products are built on the SMP™ technology and delivered via prefilled syringes with applicator tips. The company also maintains an active pipeline including a spinal cord injury cell therapy candidate being developed in collaboration with the University of Miami's Miami Project to Cure Paralysis.
Differentiator
Problem solved
Functional benefit
Brands
- Smart Materials Platform (SMP): Proprietary bioengineering platform using self-assembling peptides for developing therapeutics and devices for clinical needs.
- G4Derm Plus
- Suprello
Products and services
- G4Derm Plus Biomimetic Matrix A flowable biomimetic matrix derived from Gel4Med's Smart Materials Platform (SMP), delivered via a prefilled syringe with flexible applicator tip for precise wound coverage. Forms a 3D scaffold mimicking human extracellular matrix (ECM) providing simultaneous tissue regrowth support and antibacterial bioburden protection. FDA 510(k) cleared for partial- and full-thickness wounds, diabetic ulcers, venous/arterial/mixed-etiology lower extremity ulcers, surgical wounds, and partial-thickness burns.
- Suprello Surgical Wound Matrix A next-generation, peptide-based surgical wound matrix engineered for high-risk surgical cases. Provides a resorbable scaffold supporting tissue regrowth and capillary growth, offers broad-spectrum antibacterial protection against multidrug-resistant organisms (MDROs) via cationic peptides, and conforms to incision margins to support wound closure. FDA 510(k) cleared, available as a 2-mL pre-filled syringe with applicator tip, covering 20 cm² of wound area.
Quantifiable outcome
- In swine full-thickness incisional wound model, Suprello achieved complete tissue apposition and full closure (100% re-epithelialization) of MRSA-infected wounds with complete material resorption by Day 7 post-op
- +3 more outcomes
Companies that use Gel4Med
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Gel4Med technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Gel4Med partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Summit Products Group and MiMEDX Group, Inc.coreDistribution collaboration to expand acute-care and surgical-suite market access for G4Derm Plus Biomimetic Matrix. Summit Products Group distributes G4Derm Plus alongside MiMEDX's portfolio of surgical and wound care products, leveraging MiMEDX's established GPO and IDN contracting capabilities to accelerate hospital-system adoption.
- Centers for Medicare and Medicaid Services (CMS)coreCMS assigned unique Healthcare Common Procedure Coding System (HCPCS) Level II code A2037 to G4Derm Plus, enabling standardized billing and insurance coverage for the product.
- Spartan MedicalcorePartnership to supply G4Derm Plus and Suprello to VA and DoD medical facilities nationwide. Spartan Medical is a trusted leader in medical solutions to Veterans Affairs Medical Centers and Department of Defense Military Treatment Facilities.
- University of Miami's Miami Project to Cure ParalysiscoreCollaboration on study funded by Department of Defense to explore novel cell therapy approach for spinal cord injuries using Gel4Med's Smart Materials Platform to deliver Schwann cells. Research aims to develop treatment leading to human clinical trials and potential new drug application.
- Massachusetts General Hospital / Harvard Medical SchoolcoreClinical collaborators who published real-world evidence case series on G4Derm Plus biomimetic matrix, highlighting rapid healing of diabetic foot ulcers refractory to advanced wound treatments.
- Georgetown UniversityminorAcademic medical center collaborator listed on G4Derm Plus product page.
- University of Texas Southwestern Medical CenterminorDr. Paul Kim, Medical Director, serves as key opinion leader for G4Derm Plus in lower extremity wound care.
- Wake Forest UniversityminorAcademic medical center collaborator listed on G4Derm Plus product page.
- Mount Sinai Health SystemminorAcademic medical center collaborator listed on G4Derm Plus product page.
- Jefferson HealthminorAcademic medical center collaborator listed on G4Derm Plus product page.
- Miller School Of Medicine (University of Miami)minorAcademic collaborator partner shown in platform page pipeline section.
- University of DelawareminorAcademic collaborator partner with Dr. Darrin Poachan (Chair Of Dept. of Materials Science & Engineering) serving on Gel4Med Advisory Board.
- Harvard UniversityminorFounding institution from Harvard Innovation Labs; listed as collaborator on platform page.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Gel4Med competitors and assessment
Company assessmentDirect peers
- MiMEDX Group: Public regenerative medicine company (Nasdaq: MDXG) selling placental/amniotic tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Closest direct peer because it competes in the same skin-substitute/wound-care category and is simultaneously Gel4Med's distribution partner via Summit Products Group.
- Integra LifeSciences: Public medical device company (Nasdaq: IART) with a regenerative tissue technologies franchise including Integra Dermal Regeneration Template and other wound/surgical matrices. Directly comparable to Gel4Med's biomimetic matrix strategy, and a member of Gel4Med's advisory board (former CSO Kenneth Burhop) reinforces industry linkage.
- Organogenesis: Public regenerative medicine company (Nasdaq: ORGO) selling living-cell skin substitutes (Apligraf, Dermagraft) and amniotic products (PuraPly, NuShield) for chronic and surgical wound care. Directly competes in advanced wound care with overlapping indications including diabetic foot ulcers and venous leg ulcers.
Emerging players
- PolyNovo: ASX-listed biomaterials company developing synthetic, biodegradable dermal matrices (NovoSorb BTM) for burns and complex wound management. Closely comparable to Gel4Med's synthetic, peptide-based biomimetic matrix approach and is similarly sized but already commercializing internationally.
- Vericel: Public regenerative medicine company (Nasdaq: VCEL) marketing autologous cell therapies (MACI for cartilage repair, Epicel for burns). Comparable as a small-cap commercial regenerative-medicine peer pursuing hospital and specialty surgical channels with novel biologic/biomaterial therapies.
- Anika Therapeutics: Public regenerative medicine company (Nasdaq: ANIK) with hyaluronic-acid-based products for orthopedics, pain management, and surgical tissue repair. Comparable as a small-cap, commercial-stage regenerative-medicine peer working with surgeons and hospitals on tissue-healing applications.
Broad incumbents
- Smith & Nephew: Large global medical device company (NYSE: SNN) with a leading Advanced Wound Management portfolio (ALLEVYN, PICO, OASIS) covering dressings, NPWT, and skin substitutes. Sets the competitive baseline in advanced wound care that Gel4Med must displace in hospital and clinic accounts.
- ConvaTec: Public wound care and ostomy specialist (LSE: CTEC) with products such as AQUACEL, Foam Lite, and InnovaMatrix for advanced and surgical wound care. Broad incumbent competing across overlapping wound-care indications targeted by G4Derm Plus and Suprello.
- Coloplast: Danish-listed global leader (CPH: COLO-B) in ostomy, continence, and wound care, including the Biatain and Convatec-comparable advanced wound dressings portfolio. Represents one of the largest established players in chronic and surgical wound management globally.
- Mölnlycke Health Care: Privately held Swedish wound care and surgical solutions company with Mepilex, Mepitel, and Avance negative-pressure wound therapy. Competes broadly across hospital and surgical wound care, including advanced foam and antimicrobial dressings adjacent to G4Derm Plus's positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Gel4Med social profiles
Digital presenceGel4Med compliance and trust
Trust signalCompliance2 records
Gel4Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gel4Med leadership team
Management profileNumber of profiles
Profiles14 records
Gel4Med funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gel4Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gel4Med
What does Gel4Med do?
Gel4Med develops and commercializes FDA 510(k)-cleared, peptide-based biomimetic matrices for advanced wound care and surgical reconstruction. Its two commercial products, G4Derm Plus (a flowable biomimetic matrix for complex chronic wounds) and Suprello (a surgical wound matrix for high-risk surgical cases), are built on its proprietary Smart Materials Platform using self-assembling peptides that mimic the human extracellular matrix to support tissue regrowth while providing antibacterial protection.
Is Gel4Med a public or private company?
Gel4Med is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gel4Med founded?
Gel4Med was founded in 2023. It employs 11 to 50 people.
Where is Gel4Med based?
Gel4Med is headquartered in Allston, United States, in the North America region.
How does Gel4Med make money?
One revenue line is on record: product Sales - G4Derm Plus and Suprello.
Who are Gel4Med's main competitors?
Direct peers on record are MiMEDX Group, Integra LifeSciences and Organogenesis. Emerging players are PolyNovo, Vericel and Anika Therapeutics. Broad incumbents are Smith & Nephew, ConvaTec, Coloplast and Mölnlycke Health Care.
Does Gel4Med have an API?
No public API is recorded for Gel4Med.
What industry is Gel4Med in?
Gel4Med's product category is Wound Care Biomaterials. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3841.